Creo Medical signs comercialisation agreement with Department of Health and Social Care

May 21, 2020

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to the Company’s CROMA Advanced Energy Platform (“CROMA“) and associated devices for use in Gastrointestinal (“GI“) therapeutic endoscopy at preferential rates for a limited period.

The National Institute for Health Research (“NIHR“) Invention for Innovation (“i4i“) Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to £2 million. In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo’s suite of advanced energy surgery products.

You can read the full announcement on the Creo Investor Relations website here 

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london